Publications by authors named "R A Seaton"
Background: Antimicrobial stewardship (AMS) programmes seek to reduce the risk of antimicrobial resistance by minimizing inappropriate antimicrobial use. The SARS-CoV-2 coronavirus (COVID-19) pandemic was characterized by initial widespread use of antimicrobials in patients with COVID-19, with potential negative effects on AMS efforts.
Objective: To explore the impact of the pandemic on the AMS workforce in Scottish acute care hospitals.
Antimicrobial stability is an important consideration for treatment planning and service delivery in outpatient parenteral antimicrobial therapy (OPAT) programmes. Regulation of stability assessment varies by region, and conflicting guidance and standards exist. This leads to disparity of equity in access and limits availability of certain antimicrobials for managing infections in the outpatient setting.
View Article and Find Full Text PDFAntimicrobial therapy is essential to modern healthcare practice. However, years of injudicious use has contributed to the development of population and individual level harm from antimicrobial resistance. The frail elderly are particularly at risk from infection as well as antimicrobial adverse effects due to multimorbidity, polypharmacy and declining physiological reserve.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines COVID-19 patients in ICUs in Pakistan from March 2020 to June 2023, focusing on the prevalence and outcomes of secondary fungal infections among 636 hospitalized patients.
- - Results show that most patients were over 50 years old, with diabetes being the most common co-morbidity; 63 fungal infections occurred in 53 patients, mainly linked to the use of mechanical ventilation.
- - The overall mortality rate was 4.9%, with secondary fungal infections significantly increasing the risk; the study emphasizes the need to monitor key factors to improve patient outcomes in future cases.
The UK Antimicrobial Registry (UKAR) has been developed to capture data on real world usage of antimicrobial agents with an initial focus on those used to treat drug-resistant infections. Several industry partners have committed support for the study, which is included in the National Institute for Health and Care Research (NIHR) portfolio in England with similar arrangements in the three devolved UK nations. The two antimicrobials in the National Institute for Health and Care Excellence (NICE) subscription model pilot (cefiderocol and ceftazidime/avibactam) are included in the UKAR and future expansion of work in this area is planned.
View Article and Find Full Text PDF